Search Results
Search for other papers by Tobias Hofving in
Google Scholar
PubMed
Search for other papers by Viktor Sandblom in
Google Scholar
PubMed
Search for other papers by Yvonne Arvidsson in
Google Scholar
PubMed
Search for other papers by Emman Shubbar in
Google Scholar
PubMed
Search for other papers by Gülay Altiparmak in
Google Scholar
PubMed
Department of Medical Physics and Biomedical Engineering, Sahlgrenska University Hospital, Gothenburg, Sweden
Search for other papers by John Swanpalmer in
Google Scholar
PubMed
Search for other papers by Bilal Almobarak in
Google Scholar
PubMed
Search for other papers by Anna-Karin Elf in
Google Scholar
PubMed
Search for other papers by Viktor Johanson in
Google Scholar
PubMed
Search for other papers by Erik Elias in
Google Scholar
PubMed
Search for other papers by Erik Kristiansson in
Google Scholar
PubMed
Department of Medical Physics and Biomedical Engineering, Sahlgrenska University Hospital, Gothenburg, Sweden
Search for other papers by Eva Forssell-Aronsson in
Google Scholar
PubMed
Search for other papers by Ola Nilsson in
Google Scholar
PubMed
months) in patients with small intestinal neuroendocrine tumours (SINETs), compared with the best standard of care ( Strosberg et al. 2017 ). This has led to an FDA approval of 177 Lu-octreotate therapy for gastroenteropancreatic NETs and its inclusion
Service of Endocrinology, Department of Immunology, Department of Medical Sciences, Service of Endocrinology and Nutrition, Service of Pathology, Service of Endocrinology, Service of Immunology, Service of Digestive Surgery, Service of Digestive Diseases and CIBEREHD, Hospital Universitario de la Princesa, Universidad Autónoma de Madrid, Instituto de Investigación Sanitaria Princesa, C/Diego de León 62, Madrid 28006, Spain
Service of Endocrinology, Department of Immunology, Department of Medical Sciences, Service of Endocrinology and Nutrition, Service of Pathology, Service of Endocrinology, Service of Immunology, Service of Digestive Surgery, Service of Digestive Diseases and CIBEREHD, Hospital Universitario de la Princesa, Universidad Autónoma de Madrid, Instituto de Investigación Sanitaria Princesa, C/Diego de León 62, Madrid 28006, Spain
Search for other papers by Nicté Figueroa-Vega in
Google Scholar
PubMed
Search for other papers by Ángel Díaz in
Google Scholar
PubMed
Search for other papers by Magdalena Adrados in
Google Scholar
PubMed
Search for other papers by Cristina Álvarez-Escolá in
Google Scholar
PubMed
Search for other papers by Amalia Paniagua in
Google Scholar
PubMed
Search for other papers by Julián Aragonés in
Google Scholar
PubMed
Search for other papers by Elena Martín-Pérez in
Google Scholar
PubMed
Search for other papers by Susanna Leskela in
Google Scholar
PubMed
Search for other papers by Ricardo Moreno-Otero in
Google Scholar
PubMed
Search for other papers by Roberto González-Amaro in
Google Scholar
PubMed
Search for other papers by Mónica Marazuela in
Google Scholar
PubMed
Introduction Neuroendocrine tumors (NETs) comprise a heterogeneous group of uncommon neoplasms that include the gastroenteropancreatic (GEP)-NETs, which constitute 70% of all NETs and 2% of all digestive tract tumors ( Modlin et al . 2008 , Oberg
Search for other papers by Clemens Kratochwil in
Google Scholar
PubMed
Search for other papers by Ruben López-Benítez in
Google Scholar
PubMed
Search for other papers by Walter Mier in
Google Scholar
PubMed
Search for other papers by Sabine Haufe in
Google Scholar
PubMed
Search for other papers by Berend Isermann in
Google Scholar
PubMed
Search for other papers by Hans-Ulrich Kauczor in
Google Scholar
PubMed
Search for other papers by Peter L Choyke in
Google Scholar
PubMed
Search for other papers by Uwe Haberkorn in
Google Scholar
PubMed
Search for other papers by Frederik L Giesel in
Google Scholar
PubMed
metastatic neuroendocrine tumors (NETs) for over 10 years. Clinical studies have demonstrated objective radiologic responses in up to 30% of the patients ( Kwekkeboom et al . 2008 , Bodei et al . 2010 ). Patients with gastroenteropancreatic (GEP
Search for other papers by Federico Gatto in
Google Scholar
PubMed
Search for other papers by Leo J Hofland in
Google Scholar
PubMed
adenomas, well-differentiated gastroenteropancreatic (GEP) NET represent a major target for SSA treatment ( Oberg 2002 , Oberg et al . 2004 a , b , Batista et al . 2006 , Falconi et al . 2006 , O'Toole et al . 2006 a ). Both pancreatic NET
Search for other papers by Sara Pusceddu in
Google Scholar
PubMed
Search for other papers by Antonio Facciorusso in
Google Scholar
PubMed
Search for other papers by Luca Giacomelli in
Google Scholar
PubMed
Search for other papers by Natalie Prinzi in
Google Scholar
PubMed
Search for other papers by Francesca Corti in
Google Scholar
PubMed
Search for other papers by Monica Niger in
Google Scholar
PubMed
Search for other papers by Massimo Milione in
Google Scholar
PubMed
Search for other papers by Jorgelina Coppa in
Google Scholar
PubMed
Search for other papers by Tommaso Cascella in
Google Scholar
PubMed
Search for other papers by Iolanda Pulice in
Google Scholar
PubMed
Search for other papers by Lavinia Biamonte in
Google Scholar
PubMed
Search for other papers by Simonetta Papa in
Google Scholar
PubMed
Search for other papers by Maria Di Bartolomeo in
Google Scholar
PubMed
Search for other papers by Aashni Shah in
Google Scholar
PubMed
Search for other papers by Rodolfo Sacco in
Google Scholar
PubMed
Oncology and Hemato-Oncology Department, Università degli Studi di Milano, Milan, Italy
Search for other papers by Filippo de Braud in
Google Scholar
PubMed
Introduction Neuroendocrine tumors (NETs) of the gastro–entero–pancreatic (GEP) system are rare neoplasms that originate from the diffused endocrine system in the gastrointestinal tract and the pancreas, with extremely varying clinical
Search for other papers by Brendan M Finnerty in
Google Scholar
PubMed
Search for other papers by Maureen D Moore in
Google Scholar
PubMed
Search for other papers by Akanksha Verma in
Google Scholar
PubMed
Search for other papers by Anna Aronova in
Google Scholar
PubMed
Search for other papers by Shixia Huang in
Google Scholar
PubMed
Search for other papers by Dean P Edwards in
Google Scholar
PubMed
Search for other papers by Zhengming Chen in
Google Scholar
PubMed
Search for other papers by Marco Seandel in
Google Scholar
PubMed
Search for other papers by Theresa Scognamiglio in
Google Scholar
PubMed
Search for other papers by Yi-Chieh Nancy Du in
Google Scholar
PubMed
Search for other papers by Olivier Elemento in
Google Scholar
PubMed
Search for other papers by Rasa Zarnegar in
Google Scholar
PubMed
Search for other papers by Irene M Min in
Google Scholar
PubMed
Search for other papers by Thomas J Fahey III in
Google Scholar
PubMed
biomarkers of metastatic potential in PNETs, our group has previously shown that the loss of ubiquitin carboxyl-terminal hydrolase L1 (UCHL1) expression by CpG promoter hypermethylation is associated with metastasis in gastroenteropancreatic neuroendocrine
Laboratory of Biochemistry and Molecular Biology, Center of Neurophysiology and Neurobiology of Marseille (CRN2M), Department of Endocrinology, Anatomical Pathology Department, Nuclear Medecine, Endocrine Surgery, Department of Endocrine Surgery, Centre Hospitalo-Universitaire Conception, 147 Boulevard Baille, 13385 Marseille, France
Search for other papers by Alexandru Saveanu in
Google Scholar
PubMed
Laboratory of Biochemistry and Molecular Biology, Center of Neurophysiology and Neurobiology of Marseille (CRN2M), Department of Endocrinology, Anatomical Pathology Department, Nuclear Medecine, Endocrine Surgery, Department of Endocrine Surgery, Centre Hospitalo-Universitaire Conception, 147 Boulevard Baille, 13385 Marseille, France
Search for other papers by Mihaela Muresan in
Google Scholar
PubMed
Search for other papers by Catherine De Micco in
Google Scholar
PubMed
Search for other papers by David Taieb in
Google Scholar
PubMed
Search for other papers by Anne-Laure Germanetti in
Google Scholar
PubMed
Search for other papers by Frederic Sebag in
Google Scholar
PubMed
Search for other papers by Jean-François Henry in
Google Scholar
PubMed
Search for other papers by Laurent Brunaud in
Google Scholar
PubMed
Laboratory of Biochemistry and Molecular Biology, Center of Neurophysiology and Neurobiology of Marseille (CRN2M), Department of Endocrinology, Anatomical Pathology Department, Nuclear Medecine, Endocrine Surgery, Department of Endocrine Surgery, Centre Hospitalo-Universitaire Conception, 147 Boulevard Baille, 13385 Marseille, France
Search for other papers by Alain Enjalbert in
Google Scholar
PubMed
Search for other papers by Georges Weryha in
Google Scholar
PubMed
Laboratory of Biochemistry and Molecular Biology, Center of Neurophysiology and Neurobiology of Marseille (CRN2M), Department of Endocrinology, Anatomical Pathology Department, Nuclear Medecine, Endocrine Surgery, Department of Endocrine Surgery, Centre Hospitalo-Universitaire Conception, 147 Boulevard Baille, 13385 Marseille, France
Search for other papers by Anne Barlier in
Google Scholar
PubMed
( Reubi & Laissue 1995 ). SRIF analogs (octreotide and lanreotide) are widely used in the treatment of pituitary GH tumors and gastroenteropancreatic neuroendocrine (GEP-NETs) ( Invitti et al . 1993 , Kopf et al . 1997 , Feelders et al . 2009 , Oberg
Search for other papers by G A Kaltsas in
Google Scholar
PubMed
Search for other papers by D Papadogias in
Google Scholar
PubMed
Search for other papers by P Makras in
Google Scholar
PubMed
Search for other papers by A B Grossman in
Google Scholar
PubMed
In-octreotide represents the imaging modality of choice in the initial evaluation of gastroenteropancreatic (GEP) and islet cell tumours, exhibiting a sensitivity of 67–100%; it can identify clinically unsuspected lesions and optimize the overall
Search for other papers by Kathrin Zitzmann in
Google Scholar
PubMed
Search for other papers by George Vlotides in
Google Scholar
PubMed
Search for other papers by Stephan Brand in
Google Scholar
PubMed
Search for other papers by Harald Lahm in
Google Scholar
PubMed
Search for other papers by Gerald Spöttl in
Google Scholar
PubMed
Search for other papers by Burkhard Göke in
Google Scholar
PubMed
Search for other papers by Christoph J Auernhammer in
Google Scholar
PubMed
activity patterns in gastroenteropancreatic neuroendocrine tumours . Endocrine-Related Cancer 18 181 – 192 . doi:10.1677/ERC-10-0126 . Koseoglu S Lu Z Kumar C Kirschmeier P Zou J 2007 AKT1, AKT2 and AKT3-dependent cell survival is cell
Search for other papers by Nicola Fazio in
Google Scholar
PubMed
Molecular Medicine Program, University of Pavia, Pavia, Italy
Search for other papers by Lorenzo Gervaso in
Google Scholar
PubMed
Search for other papers by Thorvardur R Halfdanarson in
Google Scholar
PubMed
Search for other papers by Mohamad Sonbol in
Google Scholar
PubMed
Search for other papers by Rachel A Eiring in
Google Scholar
PubMed
Search for other papers by Sara Pusceddu in
Google Scholar
PubMed
Search for other papers by Natalie Prinzi in
Google Scholar
PubMed
Search for other papers by Benedetta Lombardi Stocchetti in
Google Scholar
PubMed
Search for other papers by Simona Grozinsky-Glasberg in
Google Scholar
PubMed
Search for other papers by David J Gross in
Google Scholar
PubMed
Search for other papers by Thomas Walter in
Google Scholar
PubMed
Search for other papers by Patrick Robelin in
Google Scholar
PubMed
Search for other papers by Catherine Lombard-Bohas in
Google Scholar
PubMed
Search for other papers by Samuele Frassoni in
Google Scholar
PubMed
Search for other papers by Vincenzo Bagnardi in
Google Scholar
PubMed
Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy
Search for other papers by Lorenzo Antonuzzo in
Google Scholar
PubMed
Search for other papers by Clotilde Sparano in
Google Scholar
PubMed
Search for other papers by Sara Massironi in
Google Scholar
PubMed
Search for other papers by Fabio Gelsomino in
Google Scholar
PubMed
Search for other papers by Alberto Bongiovanni in
Google Scholar
PubMed
Search for other papers by Nicoletta Ranallo in
Google Scholar
PubMed
Search for other papers by Salvatore Tafuto in
Google Scholar
PubMed
Search for other papers by Maura Rossi in
Google Scholar
PubMed
Search for other papers by Mauro Cives in
Google Scholar
PubMed
Search for other papers by Ibrahim Rasul Kakil in
Google Scholar
PubMed
Search for other papers by Hytam Hamid in
Google Scholar
PubMed
Search for other papers by Alessandra Chirco in
Google Scholar
PubMed
Search for other papers by Michela Squadroni in
Google Scholar
PubMed
Search for other papers by Anna La Salvia in
Google Scholar
PubMed
Search for other papers by Jorge Hernando in
Google Scholar
PubMed
Search for other papers by Johannes Hofland in
Google Scholar
PubMed
Search for other papers by Anna Koumarianou in
Google Scholar
PubMed
Search for other papers by Sabrina Boselli in
Google Scholar
PubMed
Search for other papers by Darina Tamayo in
Google Scholar
PubMed
Search for other papers by Cristina Mazzon in
Google Scholar
PubMed
Search for other papers by Manila Rubino in
Google Scholar
PubMed
Search for other papers by Francesca Spada in
Google Scholar
PubMed
Capdevila J Pavel M Thawer A Baudin E O'Toole D Herrmann K Welin S Grozinsky-Glasberg S de Herder WW , 2021 Practical recommendations for the management of patients with gastroenteropancreatic and thoracic (carcinoid) neuroendocrine